September 24, 2026 11:45 ET | Source: Transgene S.A. Transgene S.A.
Rapport Semestriel 2026
Pièce jointe
Transgene Reports Continued Clinical Progress and Q3 2026 Financial Update
First Patient Dosed in Phase 1 Trial Evaluating Transgene’s and BioInvent's BT-001 in Patients with Rectal Cancer
